Comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics"

Hilma Hólm, Patrick Sulem, Vinicius Tragante, Unnur Thorsteinsdottir, Daniel F. Gudbjartsson, Kari Stefansson*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish
Article numberabe8497
JournalScience Translational Medicine
Issue number622
Publication statusPublished - 1 Dec 2021

Cite this